Boris Y. Alekseev

Moscow, MOW 125284, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Transcriptome Profiling of Prostate Cancer, Considering Risk Groups and the TMPRSS2-ERG Molecular Subtype.

Transcriptome Profiling of Prostate Cancer, Considering Risk Groups and the TMPRSS2-ERG Molecular Subtype.

Journal: International journal of molecular sciences

Published: April 07, 2023

ALDH3A2, ODF2, QSOX2, and MicroRNA-503-5p Expression to Forecast Recurrence in TMPRSS2-ERG-Positive Prostate Cancer.

ALDH3A2, ODF2, QSOX2, and MicroRNA-503-5p Expression to Forecast Recurrence in TMPRSS2-ERG-Positive Prostate Cancer.

Journal: International journal of molecular sciences

Published: September 14, 2022

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.

Journal: BMC cancer

Published: August 19, 2022

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.

Journal: JAMA oncology

Published: December 23, 2021

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 02, 2021

Case of Hereditary Papillary Renal Cell Carcinoma Type I in a Patient With a Germline MET Mutation in Russia.

Case of Hereditary Papillary Renal Cell Carcinoma Type I in a Patient With a Germline MET Mutation in Russia.

Journal: Frontiers in oncology

Published: October 16, 2019

Bioinformatic identification of differentially expressed genes associated with prognosis of locally advanced lymph node-positive prostate cancer.

Bioinformatic identification of differentially expressed genes associated with prognosis of locally advanced lymph node-positive prostate cancer.

Journal: Journal of bioinformatics and computational biology

Published: March 15, 2019

Autoantibody against arrestin-1 as a potential biomarker of renal cell carcinoma.

Autoantibody against arrestin-1 as a potential biomarker of renal cell carcinoma.

Journal: Biochimie

Published: August 15, 2018

HK3 overexpression associated with epithelial-mesenchymal transition in colorectal cancer.

HK3 overexpression associated with epithelial-mesenchymal transition in colorectal cancer.

Journal: BMC genomics

Published: March 06, 2018

Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer.

Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer.

Journal: BMC genomics

Published: January 21, 2017

Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis.

Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis.

Journal: Disease markers

Published: February 09, 2015

Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways.

Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways.

Journal: Oncotarget

Published: October 10, 2014

Showing 1-12 of 14

Last Updated: 09/26/2026